• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Catheter Precision Inc.

    9/12/24 7:56:28 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    SC 13G 1 ea0214376-13gintra_catheter.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.    )*

     

    Catheter Precision, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    74933X609

     

    (CUSIP Number)

     

    September 3, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    162,005
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    149,505
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    162,005 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    9.5% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 2 of 8

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    162,005
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    149,505
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    162,005 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    9.5% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    162,005
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    149,505
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    162,005 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    9.5% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Catheter Precision, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1670 Highway 160 West, Suite 205

    Fort Mill, SC 29708

     

    Item 2.

     

    (a)Name of Person Filing

     

    (b)Address of Principal Business Office or, if none, Residence

     

    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    74933X609

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4.Ownership.

     

    (a) and (b):

     

    (i)Immediately following the consummation of the underwritten public offering by the Issuer on September 3, 2024 (the “Offering”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 6, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 133,632 shares of Common Stock, which consisted of (i) 132,000 shares of Common Stock held by Intracoastal and (ii) 1,632 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 1,336,029 shares of Common Stock outstanding immediately following the consummation of the Offering as reported by the Issuer, plus (2) 1,632 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 366,368 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 500,000 shares of Common Stock issuable upon exercise of a second warrant held by (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 500,000 shares of Common Stock issuable upon exercise of a third warrant held by (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 500,000 shares of Common Stock issuable upon exercise of a fourth warrant held by (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (V) 1,650 shares of Common Stock issuable upon exercise of a fifth warrant held by (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (VI) 1,650 shares of Common Stock issuable upon exercise of a sixth warrant held by (“Intracoastal Warrant 6”) because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (VII) 194 shares of Common Stock issuable upon exercise of a seventh warrant held by (“Intracoastal Warrant 7”) because Intracoastal Warrant 7 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (VIII) 111 shares of Common Stock issuable upon exercise of an eight warrant held by (“Intracoastal Warrant 8”) because Intracoastal Warrant 8 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 8 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,003,605 shares of Common Stock.

     

    Page 6 of 8

     

     

      (ii) As of the close of business on September 12, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 162,005 shares of Common Stock, which consisted of (i) 68,200 shares of Common Stock held by Intracoastal, (ii) 93,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (iii) 194 shares of Common Stock issuable upon exercise of Intracoastal Warrant 7 and (iv) 111 shares of Common Stock issuable upon exercise of Intracoastal Warrant 8, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.5% of the Common Stock, based on (1) 1,336,029 shares of Common Stock outstanding immediately following the consummation of the Offering as reported by the Issuer, plus (2) 274,500 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1, (3) 93,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (4) 194 shares of Common Stock issuable upon exercise of Intracoastal Warrant 7 and (5) 111 shares of Common Stock issuable upon exercise of Intracoastal Warrant 8. The foregoing excludes (I) 500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 500,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 1,650 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (V) 1,650 shares of Common Stock issuable upon exercise of Intracoastal Warrant 6 because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,665,305 shares of Common Stock.

      

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:       0     .

     

    (ii)Shared power to vote or to direct the vote:      162,005      .

     

    (iii)Sole power to dispose or to direct the disposition of      0     .

     

    (iv)Shared power to dispose or to direct the disposition of      149,505      .

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 12, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 8 of 8

     

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision to Attend the Annual European Heart Rhythm Association Conference

    FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026. EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right. Davi

    4/8/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    New LockeT Data Accepted in Leading Electrophysiology Journal

    FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the manuscript titled "Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access Closure" has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a leading medical journal in the field of electrophysiology. This publication confirmed the safety and efficacy of LockeT for large-bore venous closure in 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring LBVA. These

    4/6/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/31/26 4:55:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Catheter Precision Inc.

    10-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/31/26 11:07:34 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Catheter Precision Inc.

    DEFA14A - Catheter Precision, Inc. (0001716621) (Filer)

    3/23/26 4:16:10 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care